17 November 2017 - - The board of directors of Parsippany, New Jersey-based serious infectious disease care and cardiovascular care specialist The Medicines Company (NASDAQ: MDCO) has appointed Fredric N. Eshelman, PharmD., the company's current chairman of the board, to the newly created position of executive chairman, and Geno Germano as a new, independent director of the company, effective immediately, the company said.
Eshelman has served as a director and non-executive chairman of the company's board since August 2015.
As executive chairman, he will continue to work with CEO, Clive Meanwell, M.D., Ph.D., and senior management of the company, to shape and execute the company's strategy and direction, as well as other key business initiatives, subject in all cases to the direction of the board of directors.
Germano, a pharmaceutical industry executive with over 30 years of leadership experience, was most recently president of Intrexon Corp.
He previously held the position of group president of the Global Innovative Pharma Business of Pfizer, Inc., where he led a growing global USD 14bn business with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas.
The Medicines Company's mission is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians, and providers in serious infectious disease care and cardiovascular care. The company is headquartered in Parsippany, New Jersey, with global innovation centers in California and Switzerland.